Lipid management and cholesterol goal attainment in Norway

American Journal of Cardiovascular Drugs

Volumn 6, Issue 2, 2006, Pages 121-128

  Ose, Leiv ^a   Skjeldestad, Finn E ^b   Bakken, Inger J ^b   Levorsen, Andŕee ^c   Alemao, Evo A ^c   Yin, Don D ^c   Borgstr̈om, Fredrik ^d,e   J̈onsson, Linus ^d,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SINTEF   (Norway)

^c MERCK RESEARCH LABORATORIES   (United States)

^d STOCKHOLM HEALTH ECONOMICS   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OMEGA 3 FATTY ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; DATA BASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NORWAY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; REGISTER; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NORWAY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645227797     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606020-00006     Document Type: Article

References (40)

1. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham study. Ann Intern Med 1971 Jan; 74 (1): 1-12
2. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982 Sep; 248 (12): 1465-77
3. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987 Apr; 257 (16): 2176-80
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984 Jan; 251 (3): 365-74
5. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987 Nov; 317 (20): 1237-45
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov; 344 (8934): 1383-9
7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov; 333 (20): 1301-7
8. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct; 335 (14): 1001-9
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May; 279 (20): 1615-22
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul; 360 (9326): 7-22
11. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
12. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67
13. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
14. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun; 361 (9374): 2005-16
15. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar; 291 (9): 1071-80
16. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003 Sep; 24 (17): 1601-10
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 May; 285 (19): 2486-97
18. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 Feb; 160 (4): 459-67
19. Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001 Apr; 110 Suppl. 6A: 17-23S
20. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998 Jun; 158 (11): 1238-44
21. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy 2001 Jul; 21 (7): 807-17
22. Olson KL, Tsuyuki RT. Patients' achievement of cholesterol targets: a cross-sectional evaluation. Am J Prev Med 2003 Nov; 25 (4): 339-42
23. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results: EUROASPIRE Study Group: European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997 Oct; 18 (10): 1569-82
24. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001 Apr; 22 (7): 554-72
25. EUROASPIRE I and II Group: European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries: EUROASPIRE I and II Group: European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001 Mar; 357 (9261): 995-1001
26. Svilaas A, Ose L, Risberg K, et al. Treatment goals for blood lipids in high risk patients of atherosclerotic disease [in Norwegian]. Tidsskr Nor Laegeforen 2001 Mar; 121 (9): 1059-63
27. Svilaas A, Risberg K, Thoresen M, et al. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000 Dec; 86 (11): 1250-3, A6
28. Tonstad S, Rosvold EO, Furu K, et al. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004; 255: 494-502
29. Lindgren P, Borgstr̈om F, St°alhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005 Dec; 12 (6): 530-4
30. Van Ganse E, Souchet T, Laforest L. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular vascular outcomes: an observational study. Atherosclerosis 2006 Mar; 185 (1): 58-64. Epub 2005 Jul 20
31. Van Ganse E, Souchet T, Laforest L, et al. Effectiveness of lipid-lowering therapy in French primary care. Br J Clin Pharmacol 2005 Apr; 59 (4): 456-63
32. Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with CHD: relation to pretreatment LDL cholesterol, pretreatment CHD risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005 Feb; 12 (1): 37-45
33. The Reality Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the Reality Study. Pharmacoeconomics 2004; 22 Suppl. 3: 1-12
34. Pyorala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994 Oct; 110 (2): 121-61
35. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718-24
36. Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002; 53: 375-8
37. Durack-Brown I, Giral P, d'Ivernois J-F, et al. Patients' and physicians' perceptions and experience of hypercholesterolemia: a qualitative study. Br J Gen Pract 2003; 53: 851-7
38. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596-604
39. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-65
40. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 Suppl. 3: 13-23